Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126786 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
A Phase 2 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT03126786 is a Phase 2 study that has completed, run by Clearside Biomedical. The registered enrollment target is 71 participants.
The verdict
NCT03126786, a Phase 2 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
Interventions
- DRUG SC CLS-TA
- DRUG IVT aflibercept
- DRUG Sham SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2018-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03126786
The ClinicalTrials.gov registry entry for NCT03126786 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SC CLS-TA is the first listed.
NCT03126786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03126786 about?
NCT03126786 is a clinical study titled "Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema". The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
What is the current status of trial NCT03126786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2017-07-11. Estimated completion is 2018-04-17.
What interventions are being tested in trial NCT03126786?
The interventions under investigation include: SC CLS-TA (DRUG), IVT aflibercept (DRUG), Sham SC (DRUG).
Who is sponsoring clinical trial NCT03126786?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.